Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.34 |
| ▸ | AHCY | P23526 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9445335 | 0.82 | ALDH1A1 (0.54) | ADORA3ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL8912238 | 0.82 | ALDH1A1 (0.54) | ADORA3ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL8913594 | 0.82 | ALDH1A1 (0.54) | ADORA3ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL12642438 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL9386094 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL8913486 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL6517600 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL9386090 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL8913491 | 0.80 | ADORA3 (0.56) | ADORA3STING1 | |
| SCHEMBL2911889 | 0.76 | AHCY (0.44) | ADORA3LMNAMAPK1AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | claimed |
| EP-1658302-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | Idenix (Cayman) Limited (KY) | 2006-05-24 | — | — | EP | claimed |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | IDENIX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | claimed |
| WO-2005009418-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX (CAYMAN) LIMITED (KY) | 2005-02-03 | — | — | WO | claimed |
| US-9186369-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | INDENIX PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8742101-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1658302-B1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS INC (US) | 2010-08-25 | — | — | EP | disclosed |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| EP-1658302-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | Idenix (Cayman) Limited (KY) | 2006-05-24 | — | — | EP | disclosed |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | IDENIX PHARMACEUTICALS, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005009418-A2 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING DISEASES CAUSED BY FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX (CAYMAN) LIMITED (KY) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | PAX8 1511/4885ADORA3 236/4885HPGD 1866/4885 |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | PAX8 1511/4885ADORA3 236/4885HPGD 1866/4885 |
| US-20050075309-A1 | Treatment of pestivirus, flavivirus and hepatitis C virus infection by administering tan effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine;viricides; nontoxic; side effects reduction | PNP, TPMT, HAVCR2 | PAX8 1957/4885ADORA3 503/4885HPGD 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.